Expansion of restricted cellular immune responses to HIV-1 envelope by vaccination: IL-7 and IL-12 differentially augment cellular proliferative responses to HIV-1

Clinical and Experimental Immunology

Volumn 108, Issue 2, 1997, Pages 243-250

  Kim, J H ^a,c   Loveland, J E ^b   Sitz, K V ^a   Ratto Kim, S ^b   Mclinden, R J ^b   Tencer, K ^b   Davis, K ^b   Burke, D S ^a   Boswell, R N ^a   Redfield, R R ^c   Birx, D L ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

HIV 1; IL 12; IL 7; T cell

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; IMMUNOLOGICAL ADJUVANT; PLACEBO; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 7; TETANUS TOXOID; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EFFECTOR CELL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VIRUS ENVELOPE;

EID: 8244251419     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.d01-1006.x     Document Type: Article

References (37)

1. Clark SJ, Saag MS, Decker WD et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991; 324:954-60.
2. Daar ES, Moudgh T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991; 324:961-4.
3. Michael NL, Vahey M, Burke DS, Redfield RR. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. J Virol 1992; 66:310-6.
4. Pantaleo G, Graziosi C, Demarest JF et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent sage of disease. Nature 1993; 362:355-8.
5. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT. Massive covert infection of helper T lymphocytes and macrophages by HIV durine the incubation period of AIDS. Nature 1993; 362:359-62.
6. McNicholl JM, McDougal JS. Immunologic escape as a mechanism of viral persistence in HIV-1 infection. Sem Virol 1994; 5:307-17.
7. Grimaldi LME, Roos RP, Devare SG, Robey WG, Casey JM, Gurney ME, Apatoff BR, Lazzarin A. Restricted heterogeneity of antibody to gp120 and p24 in AIDS. J Immunol 1988; 141:114-7.
8. D'Amelio R, Biselli R, Nisini PM et al. Spectrotype of anti-gp120 antibodies remains stable during the course of HIV disease. J Acquir Immune Defic Syndr 1992; 5:930-5.
9. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. N Engl J Med 1985; 313:79-84.
10. Antonen J, Krohn K. Interleukin 2 production in HTLV-III/LAV infection: evidence of defective antigen-induced, but normal mitogen-induced IL-2 production. Clin Exp Immunol 1986; 65:489-96.
11. Ranki A, Mattinen S, Yarchoan R, Broder S, Ghrayeb J, Lähdevirta J, Krohn K. T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS 1989; 3:63-69.
12. Borkowsky W, Krasinski K, Moore T, Papevangelou V. Lymphocyte proliferative responses to HIV-1 envelope and core antigens by infected and uninfected adults and children. AIDS Res Hum Retroviruses 1990; 6:673-8.
13. Poli G, Fauci AS. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses 1992; 8:191-7.
14. + T-lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. Proc Natl Acad Sci USA 1990; 87:4818-22.
15. + cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991; 87:1462-6.
16. Afonso LCC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263:235-7.
17. Bui T, Dykers T, Hu S-L, Faltynek CR, Ho RJY. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein. J Acquir Immune Defic Syndr 1994; 7:799-806.
18. Kim JH, Sitz KV, Ratto S, McLinden RJ, Tencer K, Mosca JD, Birx DL, Redfield RR. Cytokine gene therapy for HIV: immunological effects of antigen-inducible expression of interleukin 7 in HIV- and tetanus-toxoid-specific T-cells. Clin Res 1994; 42:282A.
19. Chehimi J, Starr SE, Frank I, D'Andrea A, Ma X, MacGregor RR, Sennelier J, Trinchieri G. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994; 179:1361-6.
20. Clerici M, Lucey DR, Berzofsky JA et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993; 262:1721-4.
21. Redfield RR, Birx DL, Ketter N et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991; 324:1677-84.
22. Birx DL, Rhoads JL, Wright JC, Burke DS, Redfield RR. Immunologic parameters in early stage HIV-seropositive subjects associated with vaccine responsiveness. J Acquir Immune Defic Syndr 1991; 4:188-96.
23. Redfield RR, Wright DC, Tramont EC. The Walter Reed Staging classification for HTLV-III/LAV infection. New Engl J Med 1986; 314:131-2.
24. Kim JH, Ratto S, Sitz KV et al. Consequences of stable transduction and antigen-inducible expression of the human interleukin-7 gene on tetanus-toxoid specific T cells. Hum Gene Ther 1994; 5:1457-66.
25. Biselli R, Loomis LD, Del Bono V, Burke DS, Redfield RR, Birx DL. Immunization of HIV-infected patients with rgp160 modulation of anti-rgp120 antibody spectrotype. J Acquir Immune Defic Syndr 1994; 7:1016-24.
26. Morrissey PJ, Goodwin RG, Nordan RP et al. Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T-cells. J Exp Med 1989; 169:707-16.
27. Welch PA, Namen AE, Goodwin RG, Armitage R, Cooper MD. Human IL-7: a novel T-cell growth factor. J Immunol 1989; 143:3562-7.
28. Manca F, Habeshaw J, Dalgleish A. The naive repertoire of human T helper cells specific for gp120, the envelope glycoprotein of HIV. J Immunol 1991; 146:1964-71.
29. c chain of the IL-2 receptor. Science 1994; 266:1039-42.
30. Chehimi J, Starr SE, Frank I et al. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992; 175:789-96.
31. Trinchieri G, Scott P. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 1994; 15:460-3.
32. Shu U, Demeure CE, Byun D-G, Podlaski F, Stern AS, Delespesse G. Interleukin 12 exerts a differential effect on the maturation of neonatal and adult human CD45RO CD4 T cells. J Clin Invest 1994; 94:1352-8.
33. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994; 15:575-81.
34. Clerici M, Hakim FT, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, Shearer GM. Changes in interleukin-2 and interleukin-4 production in asymptomatic human immunodeficiency virus-seropositive individuals. J Clin Invest 1993; 91:759-65.
35. Graziosi C, Pantaleo G, Gantt KR, Fortin J-P, Demarest JF, Cohen OJ, Sékaly RP, Fauci AS. Lack of evidence for the dichotomy of Th1 and Th2 predominance in HIV-infected individuals. Science 1994; 265:248-52.
36. Maggi E, Mazzetti M, Ravina A et al. Ability of HIV to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells. Science 1994; 265:244-8.
37. + cell depletion. Cell 1988; 54:561-75.